News from the cutting edge:
"Aegis reiterated their buy rating on shares of Caladrius Biosciences (NASDAQ:CLBS) in a research report report published on Friday morning, MarketBeat Ratings reports. Aegis currently has a $2.00 price target on the stock.
A number of other analysts have also commented on the stock. HC Wainwright lowered shares of Caladrius Biosciences from a buy rating to a neutral rating in a report on Friday, January 8th. Maxim Group lowered shares of Caladrius Biosciences from a buy rating to a hold rating in a report on Thursday, January 7th. Zacks Investment Research raised shares of Caladrius Biosciences from a hold rating to a buy rating in a report on Thursday, November 26th. Finally, WBB Securities reaffirmed a buy rating and set a $7.00 target price on shares of Caladrius Biosciences in a report on Thursday, September 24th. Four analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The company currently has an average rating of Hold and a consensus target price of $5.80."
What did they base this on?
"Caladrius Biosciences, Inc., formerly NeoStem, Inc., is a clinical-stage biopharmaceutical company. The Company’s clinical program is based on its dendritic cell and cancer cell technology. It is focused on the development of a cancer treatment designed to focus the cells responsible for tumor growth and metastasis, known as cancer or tumor initiating cells (NASDAQ:CLBS). Its lead product candidate based on this platform technology is NBS20 (targeted cancer immunotherapy), which is in Phase II trials focuses on malignant melanoma as an initial indication. Its therapeutic platforms also include ischemic repair (CD34 Cell Program) and immune modulation (T Regulatory Cell Program). Its CD34 Cell Program develops therapies designed to address diseases and conditions caused by ischemia. Its product candidate in CD34 Cell Program is NBS10, which has completed Phase I clinical trials. Under T Regulatory Cell Program, the Company is developing NBS03D, which is in the Phase I clinical trial stage."
Caveat lector, but always good to see target prices multiples of current price. even if the reasons given are rather suss.
